A novel MPL point mutation resulting in thrombopoietin-independent activation

Leukemia

Volumn 16, Issue 8, 2002, Pages 1500-1506

  Abe, M ^a   Suzuki, K ^a   Inagaki, O ^a   Sassa, S ^a   Shikama, H ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Ba F3; Growth; MPL; Phosphorylation; Point mutation; Thrombopoietin

Indexed keywords

AMINO ACID; CYTOKINE RECEPTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE B; PROTEIN SHC; RAF PROTEIN; RAS PROTEIN; SERINE; STAT PROTEIN; THROMBOPOIETIN; TRYPTOPHAN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL GROWTH; CONTROLLED STUDY; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 0036050145     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402554     Document Type: Article

References (45)

1. Control of thrombocytopoiesis: Current state of the art
2. Thrombopoietin: The primary regulator of platelet production
3. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional
4. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors
5. Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development
6. Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice
7. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells
8. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl
9. Thrombocytopenia in c-mpl-deficient mice
10. Role of c-mpl in early hematopoiesis
11. Tyrosine-599 of the c-Mpl receptor is required for Shc phosphorylation and the induction of cellular differentiation
12. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl
13. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets
14. TPO/c-mpl ligand induces tyrosine phosphorylation of multiple cellular proteins including proto-oncogene products, Vav and c-Cbl, and Ras signaling molecules
15. Thrombopoietin signal transduction requires functional JAK2, not TYK2
16. The thrombopoietin receptor can mediate proliferation without activation of the Jak-STAT pathway
17. Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway
18. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: Role in endomitosis
19. Protein kinase C and c-myc gene activation pathways in thrombopoietin signal transduction
20. Protein kinase C mediates the mitogenic action of thrombopoietin in c-Mpl-expressing UT-7 cells
21. Thrombopoietin induces activation of the phosphatidylinositol-3′ kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL
22. Thrombopoietin-induced conformational change in p53 lies downstream of the p44/p42 mitogen activated protein kinase cascade in the human growth factor-dependent cell line M07e
23. Dissecting the thrombopoietin receptor: Functional elements of the Mpl cytoplasmic domain
24. Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo
25. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt
26. Interleukin 3-dependent survival by the Akt protein kinase
27. Phosphatidylinositol 3-kinase is involved in the protection of primary cultured human erythroid precursor cells from apoptosis
28. Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells)
29. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways
30. Dissociation of apoptosis from proliferation, protein kinase B activation, and BAD phosphorylation in interleukin-3-mediated phosphoinositide 3-kinase signaling
31. Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes
32. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity
33. Activating point mutations in the common beta subunit of the human GM-CSF, IL-3 and IL-5 receptors suggest the involvement of beta subunit dimerization and cell type-specific molecules in signalling
34. Surrogate thrombopoietin
35. Distinct regulation of glucose transport by interleukin-3 and oncogenes in a murine bone marrow-derived cell line
36. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity
37. Identification of an oncogenic form of the thrombopoietin receptor MPL using retrovirus-mediated gene transfer
38. Efficiency of signalling through cytokine receptors depends critically on receptor orientation
39. Membrane localization is not required for Mpl function in normal hematopoietic cells
40. A thrombopoietin receptor mutant deficient in Jak-STAT activation mediates proliferation but not differentiation in UT-7 cells
41. A structure-function analysis of serine/threonine phosphorylation of the thrombopoietin receptor, c-Mpl
42. Identification of a 14-3-3 binding sequence in the common beta chain of the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5 receptors that is serine-phosphorylated by GM-CSF
43. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I
44. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
45. Activating mutations of the transmembrane domain of MPL in vitro and in vivo: Incorrect sequence of MPL-K, an alternative spliced form of MPL